ADVAIR 100/50mcg; ADVAIR 250/50mcg; FLOVENT 100mcg; FLOVENT 250mcg
Проводит ГлаксоСмитКляйн ЛЛС
Страница компанииA 6-month Safety and Benefit Study of Inhaled Fluticasone Propionate/ Salmeterol Combination Versus Inhaled Fluticasone Propionate in the Treatment of 6,200 Pediatric Subjects 4-11 Years Old With Persistent Asthma
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT01462344/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза IV — препарат уже зарегистрирован. Собирают дополнительные сведения о пользе и безопасности при обычном применении.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 4–11 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 6250 чел. во всех странах исследования.
- Плановая дата окончания (11.2015) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 8 · невключение: 17
Критерии включения
- Consent to participate in the study
- Age 4-11 years old
- Male or eligible female - Female subjects should not be enrolled if they are pregnant, lactating or plan to become pregnant during the time of study participation
- Asthma diagnosis for at least 6 months
- Ability to answer questions regarding asthma control and use a metered dose inhaler and DISKUS
- A history of clinical varicella infection or recipient of a varicella vaccine in countries where the product label includes a warning regarding more serious chickenpox infections in patients using corticosteroids.
- History of at least once occurrence of asthma exacerbation within the prior 12 months
- Currently being treated for asthma and no change in asthma therapy for the last 4 weeks (Eligible subjects include: subjects with use of short-acting beta-agonist, leukotriene receptor antagonist, theophylline, or cromolyn whose asthma is not well-controlled; subjects on low-dose ICS monotherapy whose asthma is not well-controlled; subjects on low-dose ICS and one or more adjunctive therapy whose asthma is either controlled or not well-controlled asthma; subjects on medium-dose ICS monotherapy whose asthma is either controlled or not well-controlled; and subjects on medium-dose ICS and one or more adjunctive therapy whose asthma is well-controlled)
Критерии невключения
- History of life-threatening asthma
- Unstable asthma
- Current use of high-dose ICS or ICS/LABA therapy to treat asthma symptoms
- Concurrent respiratory disease: Current evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, allergic bronchopulmonary aspergillosis, cystic fibrosis, bronchopulmonary dysplasia, or other severe respiratory abnormalities other than asthma.
- Respiratory infection
- Subjects with only exercise-induced asthma
- An asthma exacerbation within the last 4 weeks or more than 4 separate exacerbations in the last 12 months
- Hospitalization for asthma within 4 weeks or more than 2 hospitalizations within the last 12 months
- Other current evidence of clinically significant uncontrolled disease/conditions of any body or organ system
- Neurological or psychiatric disease or history of drug or alcohol abuse of a subject or his/her guardian which in the opinion of the investigator could interfere with the subject's proper completion of the protocol requirements
- Participation in an interventional study or used any investigational drug for any disease state within the last 30 days
- Any adverse reaction including immediate or delayed hypersensitivity to any beta-agonist, sympathomimetic drug, or any intranasal, inhaled, or systemic corticosteroid therapy, or vehicle contained within these medication
- Severe hypersensitivity to cow's milk proteins
- Administration of prescription or over the counter medications that would significantly affect the course of asthma, or interact with sympathomimetic amines such as: anti-IgE (omalizumab), anticonvulsants (barbiturates, hydantoins, carbamazepine); polycyclic antidepressants, beta-adrenergic blockers; phenothiazines, monoamine oxidase inhibitors, or diuretics
- Potent cytochrome P450 3A4 (CYP3A4) inhibitors within the last 4 weeks (e.g., ritonavir, ketoconazole, itraconzole)
- Affiliation with investigator's site, including a immediate family member of the participating investigator, sub-investigator, study coordinator, or employee of the participating investigator.
- A Child in Care (CiC) is a child who has been placed under the control or protection of an agency, organisation, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation.
Источник: ClinicalTrials.gov, NCT01462344 · запись обновлена в реестре 6 августа 2018.
Дизайн и результаты
Что измеряют — первичные конечные точки (2), вторичных — 6
- Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal Intubation, or Asthma-related Death) — From Day 1 up to 6 months
- Number of Participants With at Least One Asthma Exacerbation Over the 6-month Study Treatment Period — From Day 1 up to 6 months
Цель исследования
The purpose of this study is to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, endotracheal intubations, and deaths) in children 4-11 years old taking inhaled fluticasone propionate/salmeterol combination is the same as those taking inhaled fluticasone propionate alone.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT01462344 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.